Literature DB >> 12514742

Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells.

Jeong-Hyeon Sohn1, Puran S Bora, Hye-Jung Suk, Hector Molina, Henry J Kaplan, Nalini S Bora.   

Abstract

Systemic tolerance can be induced by the introduction of antigen into an immune-privileged site. Here we investigated the role of complement in the induction of tolerance after intraocular injection. We found that the development of antigen-specific tolerance is dependent on a complement activation product. The ligation of the complement C3 activation product iC3b to complement receptor type 3 (the iC3b receptor) on antigen-presenting cells resulted in the sequential production of transforming growth factor-beta2 and interleukin-10, which is essential for the induction of tolerance. These observations may extend to the development of both neonatal tolerance and other forms of acquired tolerance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12514742      PMCID: PMC1821085          DOI: 10.1038/nm814

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  44 in total

Review 1.  Unraveling immune privilege.

Authors:  J W Streilein
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

2.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

3.  A novel role for TGF-beta and IL-10 in the induction of immune privilege.

Authors:  T J D'Orazio; J Y Niederkorn
Journal:  J Immunol       Date:  1998-03-01       Impact factor: 5.422

4.  An investigation of the temporal induction of cytokine mRNAs in LPS-challenged thioglycollate-elicited murine peritoneal macrophages using the reverse transcription polymerase chain reaction.

Authors:  A E Simpson; P T Tomkins; K L Cooper
Journal:  Inflamm Res       Date:  1997-02       Impact factor: 4.575

5.  Mechanism of suppression of cell-mediated immunity by measles virus.

Authors:  C L Karp; M Wysocka; L M Wahl; J M Ahearn; P J Cuomo; B Sherry; G Trinchieri; D E Griffin
Journal:  Science       Date:  1996-07-12       Impact factor: 47.728

6.  Differential expression of transforming growth factor-beta isoforms and receptors in experimental membranous nephropathy.

Authors:  S J Shankland; J Pippin; R H Pichler; K L Gordon; S Friedman; L I Gold; R J Johnson; W G Couser
Journal:  Kidney Int       Date:  1996-07       Impact factor: 10.612

7.  Reversal of immunosuppression inducible through ultraviolet-exposed skin by in vivo anti-CD11b treatment.

Authors:  C Hammerberg; N Duraiswamy; K D Cooper
Journal:  J Immunol       Date:  1996-12-15       Impact factor: 5.422

8.  Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity.

Authors:  M R Wessels; P Butko; M Ma; H B Warren; A L Lage; M C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

9.  C3d of complement as a molecular adjuvant: bridging innate and acquired immunity.

Authors:  P W Dempsey; M E Allison; S Akkaraju; C C Goodnow; D T Fearon
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

10.  Required early complement activation in contact sensitivity with generation of local C5-dependent chemotactic activity, and late T cell interferon gamma: a possible initiating role of B cells.

Authors:  R F Tsuji; G P Geba; Y Wang; K Kawamoto; L A Matis; P W Askenase
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

View more
  60 in total

1.  Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization.

Authors:  Juan Liu; Purushottam Jha; Valeriy V Lyzogubov; Ruslana G Tytarenko; Nalini S Bora; Puran S Bora
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

2.  Expression, by functional proteomics, of spontaneous tolerance in rat orthotopic liver transplantation.

Authors:  Tai-Long Pan; Pei-Wen Wang; Chao-Chen Huang; Shigeru Goto; Chao-Long Chen
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

Review 3.  Fragile privileges: autoimmunity in brain and eye.

Authors:  Hartmut Wekerle; De-ming Sun
Journal:  Acta Pharmacol Sin       Date:  2010-09       Impact factor: 6.150

4.  Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression.

Authors:  Jianguo Liu; Shanjin Cao; Sunjung Kim; Elaine Y Chung; Yoichiro Homma; Xiuqin Guan; Violeta Jimenez; Xiaojing Ma
Journal:  Curr Immunol Rev       Date:  2005-06

5.  CR2+ marginal zone B cell production of pathogenic natural antibodies is C3 independent.

Authors:  Keith M Woods; Michael R Pope; Sara M Hoffman; Sherry D Fleming
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

6.  The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function.

Authors:  Mojca Skoberne; Selin Somersan; Wanda Almodovar; Tuan Truong; Kseniya Petrova; Peter M Henson; Nina Bhardwaj
Journal:  Blood       Date:  2006-04-13       Impact factor: 22.113

7.  Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.

Authors:  Andrew W Taylor; Henry J Kaplan
Journal:  Ocul Immunol Inflamm       Date:  2010-12       Impact factor: 3.070

Review 8.  Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.

Authors:  David F Pinelli; Mandy L Ford
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

9.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

Review 10.  Genetics of rheumatic disease.

Authors:  Alex Clarke; Timothy J Vyse
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.